Search - tctmd.com

Displaying 101 - 114 of 114

Sort: Relevancy | Date

News Daily News

Interhospital Transfer for Acute MI Associated With Disruptions in Aftercare, More Readmissions

L.A. McKeown

January 27, 2016

News Daily News

La Derivación Interhospitalaria de los IAM provoca Interrupciones en los Cuidados Posteriores y Más Rehospitalizaciones

L.A. McKeown

January 27, 2016

News Daily News

High Level of Gut Metabolite Predicts Worse Outcomes in ACS Patients

Michael O'Riordan

January 12, 2016

News Daily News

Ezetimibe Fails to Garner Support for CV- Event Reduction Claim From FDA Advisory Committee

Michael O'Riordan

December 15, 2015

News Daily News

Un Comité Asesor de la FDA No Avala la Afirmación de que Ezetimibe Reduce los Episodios CV

Michael O'Riordan

December 15, 2015

News Daily News

Observational Study Hints at Real Benefits for Patients Who Take PUFAs After Acute MI

November 30, 2015

News Daily News

Un Estudio Observacional Revela los Beneficios Reales de Pacientes a Tratamiento con AGPI Post-IAM

November 30, 2015

News Conference News AHA 2015

Knowing Genetic Risk for MI Motivates Patients, Physicians to Get Cholesterol Levels Lower

Yael L. Maxwell

November 08, 2015

News Industry News

FDA approves Praxbind, the first reversal agent for the anticoagulant Pradaxa

October 20, 2015

News Industry News

New Analyses from the IMPROVE-IT Outcomes Study of VYTORIN® (ezetimibe and simvastatin) and the TECOS Cardiovascular Safety Trial of JANUVIA® Will Be Presented at the European Society of Cardiology

August 20, 2015

News Industry News

Jardiance® demonstrated cardiovascular (CV) risk reduction in people with type 2 diabetes at high risk for CV events

August 20, 2015

News Industry News

Takeda Presents Additional Data from Alogliptin's EXAMINE Cardiovascular Safety Outcomes Trial at the American Diabetes Association's 75th Scientific Sessions

June 05, 2015

News Daily News

Meta-analysis: Mortality Lower With PCI vs Medical Therapy Alone in Stable Patients With Documented Ischemia

L.A. McKeown

March 24, 2015

News Daily News

Dabigatran Cost-Effective Only for A-Fib Patients at High Stroke Risk

L.A. McKeown

June 03, 2011

Advertisement

Interhospital Transfer for Acute MI Associated With Disruptions in Aftercare, More Readmissions

La Derivación Interhospitalaria de los IAM provoca Interrupciones en los Cuidados Posteriores y Más Rehospitalizaciones

High Level of Gut Metabolite Predicts Worse Outcomes in ACS Patients

Ezetimibe Fails to Garner Support for CV- Event Reduction Claim From FDA Advisory Committee

Un Comité Asesor de la FDA No Avala la Afirmación de que Ezetimibe Reduce los Episodios CV

Observational Study Hints at Real Benefits for Patients Who Take PUFAs After Acute MI

Un Estudio Observacional Revela los Beneficios Reales de Pacientes a Tratamiento con AGPI Post-IAM

Knowing Genetic Risk for MI Motivates Patients, Physicians to Get Cholesterol Levels Lower

FDA approves Praxbind, the first reversal agent for the anticoagulant Pradaxa

New Analyses from the IMPROVE-IT Outcomes Study of VYTORIN® (ezetimibe and simvastatin) and the TECOS Cardiovascular Safety Trial of JANUVIA® Will Be Presented at the European Society of Cardiology

Jardiance® demonstrated cardiovascular (CV) risk reduction in people with type 2 diabetes at high risk for CV events

Takeda Presents Additional Data from Alogliptin's EXAMINE Cardiovascular Safety Outcomes Trial at the American Diabetes Association's 75th Scientific Sessions

Meta-analysis: Mortality Lower With PCI vs Medical Therapy Alone in Stable Patients With Documented Ischemia

Dabigatran Cost-Effective Only for A-Fib Patients at High Stroke Risk

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content